Chemoprophylaxis with Oral Ciprofloxacin in Ovarian Cancer Patients Receiving Taxol

Carlson, Jeremie; Fowler, Jeffrey M.; Saltzman, Andrew K.; Carter, Jonathan; Chen, M.D.; Mitchell, S.K.; Dünn, David L.; Carson, Linda F.; Adcock, Leon L.; Twiggs, L.

doi:10.1006/gyno.1994.1315

Cited by 17 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both have been demonstrated to be significantly reduced with oral prophylactic antimicrobial therapy. [6][7][8][9][10]17,40 The hospitalization rate in this study was found to be significantly reduced, specifically in dogs with lymphoma. Nine episodes of hospitalization occurred.…”

Section: Discussionmentioning

confidence: 51%

“…These studies have demonstrated significant reductions in mortality, hospitalization, infection, and cost of patient care. [6][7][8][9][10] Owing to concerns about the emergence of resistant infections with routine prophylactic antimicrobial use, recommendations have been made to limit antimicrobials to patients who are young, immunologically compromised, or expected to develop clinically relevant and prolonged myelosuppression. In spite of these recommendations, a recent study indicated that 45% of physicians dispense prophylactic antimicrobial care to human chemotherapy patients.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prophylactic Trimethoprim-sulfadiazine During Chemotherapy in Dogs with Lymphoma and Osteosarcoma: A Double-blind, Placebo-Controlled Study

Chretin¹,

Rassnick

Shaw³

et al. 2007

J Vet Int Med

View full text Add to dashboard Cite

Background: The administration of chemotherapy is associated with risk for morbidity. Management of chemotherapyrelated morbidity in veterinary oncology has been primarily supportive.Hypothesis: The purpose of this study was to evaluate the effect of prophylactic antimicrobial use on chemotherapyassociated morbidity in dogs with lymphoma or osteosarcoma.Animals: Dogs presenting with histologically confirmed osteosarcoma or lymphoma were eligible. Methods: Patients were randomized to receive placebo or trimethoprim-sulfadiazine for 14 days after their first doxorubicin chemotherapy. Both owner and clinician were blinded with respect to treatment. Patient assessment included CBC, physical examination and performance, and toxicosis grading on days 7 and 14. Investigated outcomes were hospitalization, suspicion of infection, gastrointestinal toxicity, neutropenia, nonhematologic toxicity, and quality of life.Results: Seventy-three dogs were enrolled; 34 had osteosarcoma, and 39 had lymphoma. Dogs receiving trimethoprimsulfadiazine (n 5 36) had a significantly reduced hospitalization rate (P 5.03), nonhematologic toxicity (P 5 0.039), grade 2-4 nonhematologic toxicity (P , .0001), grade 2-4 gastrointestinal toxicity (P 5 .007). and altered performance (P 5 .015). By group, dogs with osteosarcoma (n 5 34) that received the antimicrobial experienced fewer occurrences of nonhematologic toxicity (P 5.02) and less severe nonhematologic toxicity (P 5 .038). Dogs with lymphoma (n 5 39) had significant reductions in the occurrence of hospitalization (P 5.035), severity of nonhematologic toxicity (P 5 .036), and alterations of performance (P 5 .015).Conclusions: The use of prophylactic trimethoprim-sulfadiazine has benefit in reducing morbidity in dogs with osteosarcoma or lymphoma during the first 14 days after treatment with doxorubicin.

show abstract

Section: Discussionmentioning

confidence: 51%

mentioning

confidence: 99%

Prophylactic Trimethoprim-sulfadiazine During Chemotherapy in Dogs with Lymphoma and Osteosarcoma: A Double-blind, Placebo-Controlled Study

Chretin¹,

Rassnick

Shaw³

et al. 2007

J Vet Int Med

View full text Add to dashboard Cite

show abstract

“…One retrospective (non-randomized) evaluation of women with ovarian cancer receiving paclitaxel chemotherapy did attempt to examine the ecacy of the prophylactic delivery of oral cipro¯oxacin (Carlson et al 1994). In this series, patients (n = 62) received either no prophylaxis after paclitaxel (n =18), cipro¯oxacin (500 mg orally twice a day until the granulocyte count exceeded 1000/m 3 ) (n = 29), or ®lgrastim (granulocyte/ macrophage-colony-stimulating factor, G-CSF) (n = 15) (from day 2 after chemotherapy until the granulocyte count exceeded 1000 /mm 3 ).…”

Section: Discussionmentioning

confidence: 99%

Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropenia

Markman

Kennedy

Webster

et al. 2000

Journal of Cancer Research and Clinical Oncology

View full text Add to dashboard Cite

The development of significant neutropenia is a relatively frequent complication of cytotoxic chemotherapy of malignant disease. In an effort to develop a cost-effective management strategy to prevent serious infectious events associated with severe chemotherapy-induced neutropenia, patients treated in the Gynecological Oncology Program of the Cleveland Clinic Taussig Cancer Center have been administered ciprofloxacin, a potent broad-spectrum antibiotic, 500 mg orally twice a day, beginning at the time of documentation of grade 4 neutropenia. The antibiotic is continued until granulocyte recovery. A total of 44 patients (57 treatment courses) have been treated in this manner. There have been no complications of therapy and no episodes of subsequent infections due to ciprofloxacin-resistant organisms. Two patients required hospital admission following the development of significant fever, despite the use of ciprofloxacin. While these results are encouraging and suggest that the use of prophylactic ciprofloxacin is a highly cost-effective management approach in this setting, randomized controlled trials are necessary to define the ultimate benefit of this clinical strategy.

show abstract

Chemotherapy-induced neutropenia and fever in patients with metastatic breast carcinoma receiving salvage chemotherapy

Rahman¹,

Esparza-Guerra²,

Yap³

et al. 1997

Cancer

View full text Add to dashboard Cite

retrospective analysis, the authors evaluated the incidence of neutropenic fever, fever (41 episodes among 40 patients). The incidence of neutropenic fever did not Anderson Cancer Center, Houston, Texas.increase until the absolute neutrophil count (ANC) had decreased to less than 500/ mL, and then fever incidence had a linear relationship with decreasing ANC (linear trend, P õ 0.01). A source of infection was documented in 59% of the neutropenic fever episodes. The incidence of infection did not increase significantly until the ANC had decreased to less than 250/mL (P õ 0.01). The risk of neutropenic fever and infection was also significantly higher when patients had poor performance status or were undergoing the initial courses of chemotherapy. Patients with bone marrow metastases also had a higher frequency of fever, infection, and death, but these differences were not statistically significant. CONCLUSIONS.For patients with metastatic breast carcinoma receiving salvage chemotherapy, the risk of fever increases with decreasing ANC, but the risk of infection does not increase significantly until ANC decreases to less than 250/ mL. ship between infections and neutropenia was first described about 30 years ago in patients with acute leukemia receiving chemotherapy. 2Received July 29, 1996; revision received November 20, 1996; accepted November 20, 1996.Since then, considerable progress has been made in the management ᭧ 1997 American Cancer Society

show abstract

Chemoprophylaxis with Oral Ciprofloxacin in Ovarian Cancer Patients Receiving Taxol

Cited by 17 publications

References 0 publications

Prophylactic Trimethoprim-sulfadiazine During Chemotherapy in Dogs with Lymphoma and Osteosarcoma: A Double-blind, Placebo-Controlled Study

Prophylactic Trimethoprim-sulfadiazine During Chemotherapy in Dogs with Lymphoma and Osteosarcoma: A Double-blind, Placebo-Controlled Study

Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropenia

Chemotherapy-induced neutropenia and fever in patients with metastatic breast carcinoma receiving salvage chemotherapy

Contact Info

Product

Resources

About